# Arndt Vogel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/arndt-vogel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,995 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 82 |
| i10-index | 312 |
| Last Known Institution | University Health Network |
| OpenAlex ID | https://openalex.org/A5079645039 |
| ORCID iD | https://orcid.org/0000-0003-0560-5538 |
| Works | 761 |

## Researcher papers

- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [NASH limits anti-tumour surveillance in immunotherapy-treated HCC](https://scholariq.org/papers/nash-limits-anti-tumour-surveillance-in-immunotherapy-treated-hcc/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/biliary-tract-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/pancreatic-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry](https://scholariq.org/papers/cholangiocarcinoma-landscape-in-europe-diagnostic-prognostic-and-therapeutic/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients](https://scholariq.org/papers/role-of-the-galad-and-balad-2-serologic-models-in-diagnosis-of-hepatocellular/)
- [GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis](https://scholariq.org/papers/galad-score-detects-early-hepatocellular-carcinoma-in-an-international-cohort-of/)
- [Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO](https://scholariq.org/papers/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of-2/)
- [Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model](https://scholariq.org/papers/therapeutic-hnf4a-mrna-attenuates-liver-fibrosis-in-a-preclinical-model/)
- [Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial](https://scholariq.org/papers/lenvatinib-versus-sorafenib-for-first-line-treatment-of-unresectable/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)

## Researcher university

- [University Health Network](https://scholariq.org/institutions/university-health-network/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.